anti-inflammatoty and immuno-therapy - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.27 [0.32, 4.97]< 10%5 studies (5/-)36.7 %some concernnot evaluable moderatecrucial-
deaths 0.48 [0.22, 1.05]< 10%9 studies (9/-)96.6 %some concernnot evaluable moderatecrucial-
hospitalization or death 0.52 [0.36, 0.76]< 167%10 studies (10/-)100.0 %some concerncritical moderatecrucial-
clinical deterioration 0.24 [0.10, 0.56]< 10%1 study (1/-)100.0 %lownot evaluable highimportant-
clinical improvement 1.21 [1.08, 1.36]> 10%1 study (1/-)99.9 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.19 [0.78, 1.81]> 10%1 study (1/-)79.1 %lownot evaluable highimportant-
clinical improvement (28-day) 1.28 [0.84, 1.96]> 10%1 study (1/-)87.2 %lownot evaluable highimportant-
clinical improvement (7-day) 0.92 [0.51, 1.66]> 10%1 study (1/-)39.1 %lownot evaluable highimportant-
hospitalization 0.70 [0.41, 1.20]< 166%6 studies (6/-)90.1 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.76 [0.45, 1.28]< 10%3 studies (3/-)85.3 %some concernnot evaluable moderateimportant-
symptomatic Covid-19 0.56 [0.31, 1.00]< 10%1 study (1/-)97.6 %some concernnot evaluable moderateimportant-
viral clearance 1.08 [0.45, 2.60]> 172%2 studies (2/-)56.6 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.45 [0.70, 2.99]> 144%3 studies (3/-)84.4 %some concernnot evaluable moderateimportant-
ICU admission 0.54 [0.24, 1.21]< 10%1 study (1/-)93.2 %some concernnot evaluable moderatenon important-
recovery 1.10 [0.90, 1.35]> 152%3 studies (3/-)82.6 %some concernnot evaluable moderatenon important-

safety endpoints 00

emergent treatment-resistant variants 0.64 [0.08, 4.94]< 167%2 studies (2/-)66.3 %some concernnot evaluable moderateimportant-
related AE (TRAE) 1.74 [1.50, 2.03]< 10%1 study (1/-)0.0 %lownot evaluable highimportant-
serious adverse events 0.75 [0.54, 1.05]< 12%2 studies (2/-)95.1 %some concernnot evaluable moderateimportant-
adverse events 0.76 [0.54, 1.06]< 143%3 studies (3/-)94.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.